VA puts psilocybin for depression into a real veteran trial
The U.S. Department of Veterans Affairs has announced PIVOT, a multi-site study of psilocybin for veterans with treatment-resistant major depression, including people who also have PTSD. The useful news is not that a psychedelic cure has arrived. It is that a federal health system is moving the question into a large, controlled trial.
What changed
The VA said on August 5 that it is launching a new clinical trial to test the safety and effect of psilocybin for major depression in veterans. Psilocybin is the active psychedelic compound in some mushrooms. In a medical study, it is not taken alone or at home; the VA says the drug will be pharmaceutical grade, given in a controlled clinical setting, and paired with psychological support.
The trial is called Psilocybin Intervention for Veterans Overcoming Treatment-Resistant Depression, or PIVOT. The VA says it will run at five sites: Birmingham and Tuscaloosa in Alabama, Portland in Oregon, Philadelphia, and Seattle. It will enroll veterans diagnosed with treatment-resistant major depressive disorder, with or without post-traumatic stress disorder.
ClinicalTrials.gov gives the study a sharper shape. It lists PIVOT as a Phase 3, randomized, parallel trial with an estimated enrollment of 240 people. The record says participants will have two dosing sessions plus preparation and integration support. For the first session, people get assigned to one of two psilocybin dose levels. One month later, all participants get a 25 mg dose.
Why it matters
Veterans have high rates of depression and PTSD, and some do not respond to standard treatment. That does not make psilocybin a proven answer. It makes the evidence question urgent enough for a strong design.
This trial matters because it is not an open-label pilot where everyone knows what they received. The registry describes randomized allocation and quadruple masking, which means the participant, care provider, investigator, and outcome assessor do not know the first treatment assignment. That setup cannot remove every problem in psychedelic trials, because strong subjective effects can break blinding. But it is a better test than enthusiasm, clinic anecdotes, or investor slides.
The caveat readers should keep
The VA is also telling people not to self-medicate or replace current mental-health care with psychedelics or other unprescribed substances. That warning belongs near the top, not in fine print. The trial tests a drug inside a protocol with screening, support, follow-up, adverse-event tracking, and federal rules.
The timeline also argues for patience. ClinicalTrials.gov lists an estimated primary completion date in December 2030 and full completion in June 2031. If recruitment, treatment, follow-up, and analysis stay on that track, the public answer will come in years, not weeks.
So the plain read is this: the psychedelic-depression story has crossed another line from culture war and cash-pay clinics into ordinary clinical-research machinery. That is progress, but it is not permission to skip the trial.